行情

PTCT

PTCT

PTC Therapeutics
NASDAQ

实时行情|Nasdaq Last Sale

44.61
+0.07
+0.00%
盘后: 44.61 0 0.00% 16:59 04/01 EDT
开盘
43.03
昨收
44.61
最高
45.62
最低
42.59
成交量
72.10万
成交额
--
52周最高
59.89
52周最低
30.79
市值
27.94亿
市盈率(TTM)
-10.2486
分时
5日
1月
3月
1年
5年

分析师评级

11位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测PTCT价格均价为61.00,最高价位86.00,最低价为45.00。

EPS

PTCT 新闻

更多
  • FDA Decisions on 5 Drugs Expected in 2nd Quarter
  • GuruFocus.com · 2天前
  • Do Hedge Funds Love PTC Therapeutics, Inc. (PTCT)?
  • Insider Monkey · 3天前
  • Edited Transcript of PTCT earnings conference call or presentation 2-Mar-20 9:30pm GMT
  • Thomson Reuters StreetEvents · 03/25 08:48
  • The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
  • Benzinga · 03/17 15:38

所属板块

生物技术和医学研究
-4.52%
制药与医学研究
-2.91%

热门股票

代码
价格
涨跌幅

PTCT 简况

PTC Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF). PTC596 is an orally active small molecule that targets tumor stem cell populations by reducing the function, activity and amount of BMI1. RG7916 is an investigational oral therapeutic, which is in two clinical studies: SUNFISH, a trial in childhood onset (Type II/III) spinal muscular atrophy (SMA) patients, and FIREFISH, a trial in infant onset (Type I) SMA patients.
展开

微牛提供PTC Therapeutics, Inc.(NASDAQ-PTCT)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的PTCT股票新闻,以帮助您做出投资决策。